208 related articles for article (PubMed ID: 25055191)
1. Reaching low density lipoprotein cholesterol targets.
Rizos CV; Barkas F; Elisaf MS
Curr Med Res Opin; 2014 Oct; 30(10):1967-9. PubMed ID: 25055191
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
[TBL] [Abstract][Full Text] [Related]
5. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
[TBL] [Abstract][Full Text] [Related]
6. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
[TBL] [Abstract][Full Text] [Related]
7. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
[TBL] [Abstract][Full Text] [Related]
8. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
9. [Beat therapeutic inertia in dyslipidemic patient management: A challenge in daily clinical practice] [corrected].
Morales C; Mauri M; Vila L
Clin Investig Arterioscler; 2014; 26(4):193-9. PubMed ID: 24646954
[TBL] [Abstract][Full Text] [Related]
10. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
[TBL] [Abstract][Full Text] [Related]
13. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
[TBL] [Abstract][Full Text] [Related]
14. Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study.
Morales C; Plana N; Arnau A; Matas L; Mauri M; Vila À; Vila L; Soler C; Montesinos J; Masana L; Pedro-Botet J;
Clin Investig Arterioscler; 2018; 30(1):1-9. PubMed ID: 28916128
[TBL] [Abstract][Full Text] [Related]
15. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.
Robinson JG; Ray K
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588
[TBL] [Abstract][Full Text] [Related]
16. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
17. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
[TBL] [Abstract][Full Text] [Related]
20. [Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society].
Pedro-Botet J; Mostaza JM; Pintó X; Banegas JR;
Clin Investig Arterioscler; 2013; 25(4):155-63. PubMed ID: 24041476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
